Dermatology and Therapy最新文献

{"title":"An Effective and Safe Laser Treatment Strategy of Fractional Carbon Dioxide Laser for Chinese Populations with Periorbital Wrinkles: A Randomized Split-Face Trial.","authors":"Xianglei Wu, Qingqing Cen, Jian Jin, Wei Gao, Ying Shang, Linting Huang, Xiaoxi Lin","doi":"10.1007/s13555-025-01404-3","DOIUrl":"10.1007/s13555-025-01404-3","url":null,"abstract":"<p><strong>Introduction: </strong>Ablative carbon dioxide fractional laser (CO₂ AFL) can alleviate static wrinkles; however, its use in East Asian populations can predispose them to postinflammatory hyperpigmentation (PIH). We aimed to explore the optimum energy and coverage parameters of CO₂ AFL for treating static periorbital wrinkles in a Chinese population and to minimize PIH incidence.</p><p><strong>Methods: </strong>In total, 30 patients with static periorbital wrinkles were recruited. The PIH intervention side (1% hydroquinone cream every night on one periorbital area for each patient 1 month before and from the 8th day to 1 month after each treatment) and group (group A: 15‒20 mJ, 5%; group B: 10‒12.5 mJ, 15%; and group C: 12.5‒15 mJ, 10%) were determined randomly. The patients underwent two sessions of CO₂ AFL at 3-month intervals. Follow-ups were conducted until 6 months after the last treatment.</p><p><strong>Results: </strong>Overall, 20 participants (48.1 ± 13.1 years) completed all follow-ups without any serious complications. The application of hydroquinone significantly reduced PIH (p = 0.02). Both the investigators' and patients' visual evaluations demonstrated a consistent efficacy rate of 68.2% without differences between groups. The Fitzpatrick wrinkle score significantly decreased compared with pre-treatment (p < 0.01); however, a significant reduction only in group B at 3 months (p = 0.016) and 6 months (p = 0.001) post-treatment was observed. Groups B and C demonstrated significant reductions in superficial and deep wrinkles and pigmentation (p < 0.01).</p><p><strong>Conclusions: </strong>CO₂ AFL effectively reduced static periorbital wrinkles in the Chinese population. Low energy combined with high-density coverage was the most efficacious. The application of hydroquinone significantly reduced PIH incidence.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registration no. ChiCTR2400087320 (date of trial registration: 25 July 2024).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1307-1317"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-AD.","authors":"Pedro Mendes-Bastos, Elisavet Lazaridou, Tiago Torres, Charalampos Aggelakopoulos, Ioannis Katsantonis, Pantelis Aronis, Dimitrios Rigopoulos, Filomena Azevedo, Felicidade Santiago, Markos Papakonstantis, Paulo Varela, Vera S G Ribeiro, Aikaterini Kollia, Evaggelia Papadavid","doi":"10.1007/s13555-025-01414-1","DOIUrl":"10.1007/s13555-025-01414-1","url":null,"abstract":"<p><strong>Introduction: </strong>Despite significant progress observed in the treatment of atopic dermatitis (AD), a considerable number of patients with severe disease are undertreated and have inadequate symptom control. This may be due to several reasons, such as underestimation of the implications of the disease on patients, families, and society, as well as inconsistent access to effective treatment. The multidimensional disease burden of AD includes other atopic comorbidities, sleep disturbance, and functional impairment and secondary consequences, including neuropsychiatric issues (anxiety and depression) and reduced health-related quality of life.</p><p><strong>Methods: </strong>MEASURE-AD was a global, cross-sectional observational study in adolescents and adults with moderate-to-severe AD, conducted to describe disease burden, treatment patterns, and healthcare resource utilization.</p><p><strong>Results: </strong>The results concerning patients from Portugal and Greece indicate moderate-to-severe disease for most of the population with frequent disease flares. The quality of life of both adolescents and adults was greatly affected, mainly owing to itch. One out of five patients perceived that their treatment was not effectively controlling AD. Disease resulted in important out-of-pocket expenses and loss of productivity.</p><p><strong>Conclusions: </strong>Understanding and recognizing the complex burden of moderate-to-severe AD is required to encourage and guide changes in public policy for the effective management of patients.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1487-1505"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Content Validity and Psychometric Validation of an Adapted Version of the Subject Sleep Diary in Prurigo Nodularis.","authors":"Sonja Ständer, Danielle N Rodriguez, Carla Dias-Barbosa, Dina Filipenko, Jorge Puelles, Zarif K Jabbar-Lopez, Christophe Piketty, Henning Wiegmann, Shawn G Kwatra","doi":"10.1007/s13555-025-01406-1","DOIUrl":"10.1007/s13555-025-01406-1","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with prurigo nodularis (PN) often experience sleep disturbance. A psychometric evaluation was conducted to assess the suitability of a PN-adapted multi-item subject sleep diary (SSD) for measuring PN-related sleep disturbance.</p><p><strong>Methods: </strong>Content validity of the SSD was evaluated through qualitative interviews with adults with PN (N = 21). Psychometric properties of SSD parameters (sleep onset latency [SOL], wakefulness after sleep onset [WASO], total awake time [TWT], total sleep time [TST], sleep efficiency [SE], PN-related WASO [WASO-PN], number of WASO-PN, and sleep quality/refresh [SQR]) were evaluated using data from adults with moderate-to-severe PN in the phase 3 OLYMPIA trials (NCT04501666 [N = 286], NCT04501679 [N = 274]). The relationship between SSD parameters and the single-item Sleep Disturbance Numerical Rating Scale (SD-NRS) was examined using equipercentile linking.</p><p><strong>Results: </strong>Most interview participants who responded to cognitive debriefing questions understood the SSD as intended (≥ 80% for each item), confirming content validity. All SSD parameters showed good test-retest reliability. At week 16, all SSD parameters but TST showed moderate-to-strong correlations, in the expected direction, with the SD-NRS, Peak Pruritus NRS (PP-NRS), Average Pruritus (AP) NRS, Dermatology Life Quality Index (DLQI), PN-related pain frequency and intensity, Prurigo Activity and Severity Score (PAS), and/or Investigator's Global Assessment (IGA). Known-groups validity was adequate for all SSD parameters based on the Patient Global Impression of Severity-Sleep Disturbance (PGIS-SD), Patient Global Assessment of Disease (PGAD), PP-NRS, DLQI, and/or IGA. All parameters but TST were responsive to improvements on the PGIS-SD, Patient Global Impression of Change-Sleep Disturbance, PGAD, PP-NRS, AP NRS, PN-related pain intensity, DLQI, and/or IGA. Cross-sectional values or value changes of the SD-NRS were moderately to strongly correlated with SSD parameters, and equipercentile linking analyses revealed non-linear relationships between the measures.</p><p><strong>Conclusions: </strong>The findings suggest that the SSD is a fit-for-purpose measure that can be used to assess sleep disturbance in moderate-to-severe PN.</p><p><strong>Clinical trial registration: </strong>NCT04501666, NCT04501679.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1405-1426"},"PeriodicalIF":3.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream.","authors":"Timo Buhl, Andrea Bauer, Benjamin D Ehst, Jacob P Thyssen, Julie Hahn-Pedersen, Berith Fredsted Hagen, Eydna D Apol, Tove Agner","doi":"10.1007/s13555-025-01384-4","DOIUrl":"10.1007/s13555-025-01384-4","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic Hand Eczema (CHE) is a multifactorial, burdensome, inflammatory skin disease, with limited treatment options. In a double-blind dose-ranging phase 2b clinical trial, participants with CHE received delgocitinib cream, a topical pan-Janus kinase (JAK) inhibitor, or cream vehicle (clinical results published elsewhere). The objectives were to analyse patient-reported outcomes (PROs) in participants with mild and moderate to severe CHE at screening, and to investigate the impact on PROs during treatment in participants with moderate to severe CHE.</p><p><strong>Methods: </strong>Firstly, Dermatology Life Quality Index (DLQI), EQ-5D-5L, and Hand Eczema Impact Scale (HEIS) per severity were analysed at screening. Secondly, PROs were analysed in the subset of participants with moderate to severe CHE; participants receiving delgocitinib cream 20 mg/g were compared with participants receiving cream vehicle for 16 weeks.</p><p><strong>Results: </strong>At screening, mean (SD) DLQI, EQ-5D-5L, and HEIS were 8.1 (5.8), 0.788 (0.175), and 1.7 (0.8), respectively for mild CHE (n = 93), and 12.1 (6.9), 0.689 (0.236), and 2.3 (0.9) for participants with moderate to severe CHE (n = 202), respectively. Among the participants with moderate to severe CHE who received delgocitinib (n = 41), the least squares mean [SE] change from baseline to week 16 improved compared to cream vehicle (n = 38) in DLQI (- 7.1 [0.9] vs. - 4.6 [0.9]), EQ-5D-5L (0.228 [0.032] vs. 0.096 [0.034]), and HEIS (- 1.5 [0.2] vs. - 0.8 [0.2]) (P < 0.05).</p><p><strong>Conclusions: </strong>Mild CHE had a moderate effect, whereas moderate to severe CHE had a very large effect on patients' Health-Related Quality of Life at screening. Treatment with delgocitinib cream was associated with considerable improvement in PROs and represents a potentially valuable treatment option.</p><p><strong>Trial registration: </strong>ClinicalTrials. gov identifier NCT03683719.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1181-1193"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Literature Review and Network Meta-Analysis of Clinical Efficacy and Safety of Topical Treatments for Patients with Atopic Dermatitis.","authors":"Hiroyuki Murota, Takeshi Nakahara, Xinyu Wang, Miyuki Matsukawa, Hiroe Takeda, Tomohiro Kondo, Kentaro Yamato","doi":"10.1007/s13555-025-01390-6","DOIUrl":"10.1007/s13555-025-01390-6","url":null,"abstract":"<p><strong>Introduction: </strong>In Japan, atopic dermatitis (AD) is one of the most common skin diseases, with the number of patients steadily increasing in recent years. Thus, it is crucial to assess the efficacy and safety of currently existing and recently introduced new treatments.</p><p><strong>Methods: </strong>A systematic literature review (SLR) and network meta-analysis (NMA) was conducted to evaluate the clinical efficacy and safety of existing standard topical therapies and new topical treatments for AD. Medline, Embase, Cochrane, and ICHUSHI were used to select studies. The Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score were efficacy outcomes, whereas any serious adverse events (AEs), acne, and skin infections were safety outcomes. A Bayesian multiple treatment NMA with fixed effects was performed. Odds ratio with 95% credible interval (CrI) was used to compare the outcomes of different topical medications including placebo for AD.</p><p><strong>Results: </strong>A total of 11 randomised controlled trials (RCTs) conducted in adult patients with varying degrees of AD severity were selected for NMA. The systematic review showed improvement in EASI scores with difamilast 0.3% and 1% and tacrolimus 0.1% as well as in IGA score success rates with difamilast 1%, delgocitinib 3%, and tacrolimus 0.1%. According to NMA, at week 4, difamilast 1% twice daily (BID) showed a significant improvement in the IGA score and percent EASI score change from baseline versus placebo; however, compared to other comparators, point estimates numerically favoured difamilast 1% but were not statistically significant. Difamilast 1% BID showed a significantly lower incidence of acne than delgocitinib 0.3% BID. There was no statistically significant difference in the incidence of serious AEs, acne, and skin infections compared to placebo or other comparators.</p><p><strong>Conclusion: </strong>This study establishes the efficacy and safety of current topical treatment options and recently marketed delgocitinib and difamilast ointments for AD in Japan.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1045-1062"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Phase IIa Trial of Purified Candida Antigen for Common Warts: Evaluating the Safety and Efficacy Across Multiple Dosing Regimens.","authors":"Stacy R Smith, Robert E Esch, H S Nielsen, Sandra Marchese Johnson","doi":"10.1007/s13555-025-01387-1","DOIUrl":"10.1007/s13555-025-01387-1","url":null,"abstract":"<p><strong>Introduction: </strong>Non-standardized Candida albicans antigens are commonly used for the treatment of common warts (verruca vulgaris); however, clinical studies thus far have not determined optimal dosing. This study assessed three dosing schemes using Candin®, a standardized purified Candida antigen (PCA), for the treatment of common warts.</p><p><strong>Methods: </strong>This placebo-controlled, randomized phase IIa clinical trial included participants that had 3 to 20 injectable common warts on prespecified anatomical regions. PCA was administered intralesionally for up to 10 injections every 2 weeks, with adjustments to every 3 weeks for local tolerance issues. Three dosing regimens were evaluated: 0.3 or 0.5 mL into a single wart (cohorts 1 and 2, respectively), or 0.3 mL into up to four warts (cohort 3). Total injection volumes in cohorts 2 and 3 were larger than the typical off-label use of C. albicans. The primary outcome was complete resolution of injected warts, while secondary outcomes included safety, tolerability, and the clearance of untreated common warts.</p><p><strong>Results: </strong>The incidence of clearance of the primary injected wart in placebo participants was 41.9%, compared to 65.9% (relative risk [RR] 1.57; 95% confidence interval [CI] 1.02, 2.42; P = 0.03) in cohort 1, 79.5% (RR 1.89; 95% CI 1.27, 2.82; P = 0.0007) in cohort 2, and 72.5% (RR 1.74; 95% CI 1.19, 2.50; P = 0.005) in cohort 3, and treatment was well tolerated. Injection of 0.5 mL PCA into a single wart also resulted in a significantly higher rate of clearance of untreated common warts compared to placebo (RR 3.2, 95% CI 1.2, 8.0, P = 0.001).</p><p><strong>Conclusion: </strong>All three dosing regimens of PCA were safe, well tolerated, and resulted in significantly greater clearance of the primary treated wart(s) compared to placebo, but only 0.5 mL injected into a single wart was significantly better than placebo at clearing untreated warts. Typically, a volume of 0.3 mL C. albicans antigen is injected into a single wart; however, these results suggest that a larger volume of 0.5 mL may have greater benefit for patients. A phase III clinical trial is currently underway to confirm these findings.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT02393417.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1135-1152"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study.","authors":"Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, Matteo Megna, Annunziata Raimondo, Giacomo Caldarola, Nicoletta Bernardini, Anna Balato, Anna Campanati, Maria Esposito, Claudio Bonifati, Viviana Lora, Luca Potestio, Serena Lembo, Francesco Loconsole, Eleonora De Luca, Nevena Skroza, Dario Buononato, Tommaso Bianchelli, Maria Concetta Fargnoli, Nello Tommasino, Felice Primavera, Clara De Simone, Luca Bianchi, Marco Galluzzo","doi":"10.1007/s13555-025-01394-2","DOIUrl":"https://doi.org/10.1007/s13555-025-01394-2","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic inflammatory skin disorder, affecting around 2-3% of the global population. The IL-23/Th17 signaling pathway plays a critical role in disease progression. Guselkumab, an IL-23p19 monoclonal antibody, has shown substantial efficacy in clinical trials for treating moderate-to-severe plaque psoriasis. However, preliminary identification of super responders (SRe: patients achieving PASI 100 at week 20) can help optimize treatment strategies. This study aims to identify predictive factors for SRe status in patients receiving guselkumab therapy for psoriasis and to evaluate long-term effectiveness in the entire cohort and both SRe and non-super-responder (nSRe) groups to understand whether SRe status is also a predictor of long-term response to guselkumab in a real-world setting.</p><p><strong>Methods: </strong>A retrospective longitudinal study was conducted at ten Italian centers between January and October 2024. Data from 1008 patients treated with guselkumab for at least 20 weeks were analyzed. Patients were classified as SRe (PASI 100 at week 20) and nSRe. Baseline clinical and anthropometric profiles, comorbidities, and treatment history were collected. Efficacy was evaluated using PASI scores. Logistic regression analysis was performed to identify predictive factors for achieving SRe status.</p><p><strong>Results: </strong>Of 1008 patients, 581 (57.6%) were classified as SRe, while 427 (42.4%) were nSRe. SRe patients were more likely to be bio-naïve and had lower baseline PASI scores and comorbidities such as obesity, hypertension, and diabetes. Multivariate logistic regression identified obesity, prior biologic therapy, and a higher baseline PASI as negative predictors for SRe status. Guselkumab demonstrated significant long-term efficacy, with SRe patients achieving sustained PASI 100 in 85% at year 4 and 83.4% at year 5 compared to 54% and 59.2% in nSRe patients, respectively.</p><p><strong>Conclusions: </strong>Our study highlights the importance of identifying patients most likely to achieve PASI 100 early in treatment. Factors such as obesity, prior biologic experience, and baseline PASI contribute to predicting complete skin clearance, which can guide clinical decision-making and enable personalized treatment strategies.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":"15 5","pages":"1239-1250"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vitro and In Vivo Assessment of an Innovative Peeling System with Azelaic and Tranexamic Acids for Targeted Hyperpigmentation Reduction.","authors":"Russell Wong, Mariangela G de O Sichmann, James Sun, Alexis R Kim, Robert J Bianchini, Kevin D Hermanson, Louis Chabert","doi":"10.1007/s13555-025-01399-x","DOIUrl":"https://doi.org/10.1007/s13555-025-01399-x","url":null,"abstract":"<p><strong>Introduction: </strong>Melanin, derived from tyrosine, plays a pivotal role in skin pigmentation through melanogenesis. Disruptions in this process lead to hyperpigmentation, a condition affecting skin tone and quality of life. Current treatments, including chemical peels, have limitations, highlighting the need for novel solutions. Here, we present an innovative peeling system, comprising a masque and moisturizer, formulated with a novel blend of acids, including azelaic acid (AZA) and tranexamic acid (TXA), alongside known brightening and penetration-enhancing agents for a comprehensive solution to target hyperpigmentation.</p><p><strong>Methods: </strong>In vitro studies assessed the ability of the novel moisturizer to inhibit ultraviolet-A (UVA)-induced melanin accumulation in human melanocytes. In a single-center, controlled study, we assessed the efficacy of the peeling system in 33 healthy female participants aged 30-55 years with moderate-to-severe hyperpigmentation over a 6-week treatment period. Skin condition was assessed using clinical photography, 3D skin topography, and clinical expert evaluation (CEE) at baseline and 6 weeks post-treatment. Participants completed a self-evaluation questionnaire at 6 weeks post-treatment.</p><p><strong>Results: </strong>In vitro findings demonstrated a concentration-dependent inhibition of melanin accumulation by the novel moisturizer. In vivo, significant reductions in dark spot number, area, and perimeter were observed at week 6, along with improvements in skin homogeneity, contrast, and brightness. Skin tone and roughness parameters also improved significantly from baseline. These findings were supported by self-evaluation findings and improvements in CEE parameters.</p><p><strong>Conclusion: </strong>These data provide evidence for the efficacy of the innovative peeling system in reducing the appearance of hyperpigmentation over a 6-week treatment regimen in females with healthy skin and moderate-to-severe hyperpigmentation. The inclusion of AZA and TXA within the peeling system, along with active brightening and penetration-enhancing ingredients, may have synergistically facilitated the observed improvements. This multifaceted approach may address hyperpigmentation at the source, contributing to overall improvements in the appearance of the skin.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":"15 5","pages":"1209-1225"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Superficial Fungal Infections in WHIM Syndrome.","authors":"Jennifer Strong, Rutha Adhanom, Caleb S Kim, Yoshine Saito, Jasmine C Meltzer, Patrick Hallaert, Sophia Martinez, Abigail Salancy, Heidi H Kong, Edward W Cowen, Leslie Castelo-Soccio, Philip M Murphy, David H McDermott, Isaac Brownell","doi":"10.1007/s13555-025-01396-0","DOIUrl":"10.1007/s13555-025-01396-0","url":null,"abstract":"<p><strong>Introduction: </strong>WHIM syndrome is a rare autosomal dominant inborn error of immunity caused by gain-of-function mutations in the chemokine receptor CXCR4. Patients with WHIM syndrome frequently suffer from an increased risk for bacterial and viral infections, especially warts due to human papillomavirus. Associations between WHIM syndrome and fungal infections have not been previously identified. The objective of this study was to estimate the prevalence of superficial fungal infections in patients with WHIM syndrome.</p><p><strong>Methods: </strong>This retrospective single-institution cohort study assessed patients with genotype-confirmed WHIM syndrome evaluated between March 2007 and March 2024.</p><p><strong>Results: </strong>Of 45 patients with WHIM syndrome, 18 (40%) were diagnosed with at least one superficial fungal infection. These infections included dermatophytosis (n = 14, 78%), pityriasis versicolor (n = 6, 33%), and pityrosporum folliculitis (n = 1, 6%). No correlation was detected between superficial fungal infection risk and the degree of peripheral neutropenia, lymphopenia, or hypogammaglobulinemia. The median time to resolution of the longest episode of superficial dermatophytosis (skin or hair) was 171.5 (range 53-3650) days, and several patients experienced prolonged courses requiring serial retreatments.</p><p><strong>Conclusions: </strong>These findings suggest that frequent or prolonged superficial fungal infections may be a useful clinical sign to prompt consideration of a WHIM syndrome diagnosis, especially in patients with numerous cutaneous warts or other history to suggest immunodeficiency.</p><p><strong>Trial registration: </strong>Participants were enrolled in a natural history trial registered with ClinicalTrials.gov (NCT00128973).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1173-1179"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Tumoral Melanosis: A Case Series of a Rare Clinical Entity.","authors":"Cesare Ariasi, Grazia Linda Artelli, Cristina Zane, Martina Perantoni, Simone Soglia, Giuseppe La Rosa, Vincenzo Maione, Marina Venturini, Claudia Zambelli, Gaetano Licata, Mariateresa Rossi, Mariachiara Arisi","doi":"10.1007/s13555-025-01388-0","DOIUrl":"10.1007/s13555-025-01388-0","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1275-1281"},"PeriodicalIF":3.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}